Skip to main content

Essential Thrombocythemia

9
Pipeline Programs
10
Companies
11
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
1
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
8100%
+ 8 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
2
BomedemstatPhase 3Small Molecule
BomedemstatPhase 3Small Molecule
MSD
MSDIreland - Ballydine
2 programs
2
BomedemstatPhase 3Small Molecule1 trial
BomedemstatPhase 3Small Molecule1 trial
Active Trials
NCT06079879Recruiting340Est. Aug 2028
NCT06456346Recruiting300Est. Mar 2028
Sandoz
SandozAustria - Kundl
1 program
1
AnagrelidePhase 2/31 trial
Active Trials
NCT02962388Terminated13Est. Jun 2021
Incyte
IncyteDE - Wilmington
2 programs
1
1
RuxolitinibPhase 2Small Molecule1 trial
Allogeneic Hematopoietic Stem Cell TransplantationPhase 1/2
Active Trials
NCT04644211Recruiting60Est. Jul 2034
Geron
GeronCA - Foster City
1 program
1
ImetelstatPhase 2Small Molecule1 trial
Active Trials
NCT01243073Completed20Est. Apr 2015
Amoytop Biotech
Amoytop BiotechChina - Xiamen
1 program
1
Peginterferon α-2b injectionPhase 21 trial
Active Trials
NCT06552429Recruiting27Est. Sep 2027
Merck & Co.
Merck & Co.RAHWAY, NJ
3 programs
BomedemstatPHASE_2Small Molecule1 trial
IMG-7289PHASE_21 trial
BomedemstatPHASE_3Small Molecule
Active Trials
NCT04254978Completed73Est. Mar 2023
NCT04262141Active Not Recruiting4Est. Oct 2027
PharmaEssentia
PharmaEssentiaMA - Burlington
2 programs
Ropeginterferon alfa-2b-njftPHASE_21 trial
Ropeginterferon alfa-2bPHASE_31 trial
Active Trials
NCT05482971Active Not Recruiting91Est. Mar 2027
NCT04285086Active Not Recruiting174Est. Aug 2029
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
Allogeneic Hematopoietic Stem Cell TransplantationPHASE_1_21 trial
Active Trials
NCT03878199Terminated12Est. Feb 2025
Novartis
NovartisBASEL, Switzerland
1 program
AnagrelidePHASE_2_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
MSDBomedemstat
MSDBomedemstat
PharmaEssentiaRopeginterferon alfa-2b
SandozAnagrelide
Amoytop BiotechPeginterferon α-2b injection
PharmaEssentiaRopeginterferon alfa-2b-njft
IncyteRuxolitinib
Merck & Co.IMG-7289
Merck & Co.Bomedemstat
GeronImetelstat
Jazz PharmaceuticalsAllogeneic Hematopoietic Stem Cell Transplantation

Clinical Trials (11)

Total enrollment: 1,114 patients across 11 trials

NCT06456346MSDBomedemstat

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Start: Jul 2024Est. completion: Mar 2028300 patients
Phase 3Recruiting
NCT06079879MSDBomedemstat

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Start: Dec 2023Est. completion: Aug 2028340 patients
Phase 3Recruiting
NCT04285086PharmaEssentiaRopeginterferon alfa-2b

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Start: Aug 2020Est. completion: Aug 2029174 patients
Phase 3Active Not Recruiting
NCT02962388SandozAnagrelide

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Start: Jan 2017Est. completion: Jun 202113 patients
Phase 2/3Terminated
NCT06552429Amoytop BiotechPeginterferon α-2b injection

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

Start: Aug 2024Est. completion: Sep 202727 patients
Phase 2Recruiting
NCT05482971PharmaEssentiaRopeginterferon alfa-2b-njft

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Start: Sep 2022Est. completion: Mar 202791 patients
Phase 2Active Not Recruiting
NCT04644211IncyteRuxolitinib

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Start: Mar 2022Est. completion: Jul 203460 patients
Phase 2Recruiting
NCT04262141Merck & Co.IMG-7289

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Start: Oct 2020Est. completion: Oct 20274 patients
Phase 2Active Not Recruiting
NCT04254978Merck & Co.Bomedemstat

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Start: Sep 2020Est. completion: Mar 202373 patients
Phase 2Completed
NCT01243073GeronImetelstat

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera

Start: Dec 2010Est. completion: Apr 201520 patients
Phase 2Completed
NCT03878199Jazz PharmaceuticalsAllogeneic Hematopoietic Stem Cell Transplantation

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Start: Feb 2019Est. completion: Feb 202512 patients
Phase 1/2Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 1,114 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.